PICTURE OF ELIQUIS
PICTURE OF ELIQUIS

Patient Assistance for Eliquis

You may be eligible for the Bristol Myers Squibb Patient Assistance Foundation if:

  • You live in the United States or a U.S. territory*, and
  • You are being treated by a U.S. licensed prescriber, and
  • You are being treated with the medicine as an outpatient, and
  • You do not have insurance coverage for a medicine listed on this site, and
  • You were prescribed Eliquis or Orencia, and your annual household income is at or below $45,180 for a single person or $61,320 for a family of two. (Income limits are adjusted for larger families), or
  • You were prescribed a BMS medicine for cancer, ulcerative colitis, multiple sclerosis, plaque psoriasis, obstructive hypertrophic cardiomyopathy, or kidney transplant (even if your income is higher than the limits listed above), and
  • You are age 65 and over and you do not qualify for the Medicare Part D Low-Income Subsidy (LIS) program (also called “Extra Help”). Proof of denial will be required.

These are just some of the eligibility requirements. Other eligibility criteria may apply. For more information, call us at 1-800-736-0003. You can also find out if you may be eligible for BMSPAF by completing a short assessment.

*You may meet the residency requirement for our program if you live in Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, or the Northern Mariana Islands. Please contact BMSPAF for more information.

How might the Inflation Reduction Act impact my eligibility for BMSPAF?

  • The Inflation Reduction Act (IRA) expands the Medicare Part D Low-Income Subsidy (LIS) program (also called, “Extra Help”) in 2024 to extend full LIS benefits for eligible patients who earn less than 150% of the federal poverty level.
  • Patients seeking assistance from BMSPAF whose household income is less than 150% of the 2024 Federal Poverty Level (FPL) will be required to submit proof of denial from the Low-Income Subsidy (LIS/Extra Help) program before they can be considered for assistance from BMSPAF in 2024.
  • The IRA will be effectively limit the out-of-pocket maximum for Medicare Part D patients taking brand name drugs to approximately $3,300 for 2024 by eliminating a patient’s coinsurance during the catastrophic coverage phase.
  • Because the IRA may significantly lower out-of-pocket cost for medicines, patients with higher household incomes (approximately $110,000) may no longer qualify for assistance from BMSPAF.